AF
KLRS

Amalgamated Financial’s Kalaris Therapeutics KLRS Stock Holding History

Amalgamated Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$33K Buy
+209
New +$41.7K ﹤0.01% 2590

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Amalgamated Financial's KLRS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Kalaris Therapeutics (KLRS) in Q1 2022: 209 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #2590 among its holdings.

84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

  • Amalgamated Financial held 209 shares of Kalaris Therapeutics worth $33K as of Q1 2022.
  • Kalaris Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Kalaris Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2590 holding.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.